Mpox Outbreak Declared a Public Health Emergency of International Concern by WHO

WHO Director-General Dr. Tedros Adhanom Ghebreyesus determined that the upsurge of mpox in the Democratic Republic of the Congo (DRC) and a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC) under the International Health Regulations (2005) (IHR)

The serological and immunological detection of key target antigens and antibodies of the monkeypox virus, the study of the monkeypox virus infection mechanism, the research and development of drugs and vaccines, and the treatment and prevention of monkeypox are all dependent on neutral antibodies with bioactivity and recombinant monkeypox proteins developed by bioengineering technology.

The proteins of Cusabio are expressed in various systems, including eukaryotic expression systems, with yeast-expressed proteins closely mimicking native structures. Each protein undergoes stringent quality control, ensuring a purity level of over 85% as measured by SDS-PAGE.

Key recombinant monkeypox virus antigens of Cusabio

A30L: acts as an envelope protein required for virus entry into the host and cell-cell fusion and is considered to be an important target in monkeypox virus research.
A42R: is currently the only entry for a monkeypox protein.
E8L: an important gene for virus invasion into host cells. As the cell surface binding protein of MV, E8L binds to the chondroitin sulfate, allowing virions to attach to target cells during the viral invasion and replication.

These recombinant proteins are invaluable tools for basic monkeypox virus research, the development of neutralizing antibodies, and the quality control of preventive vaccines and therapeutic drugs.

References
Cusabio Recombinant Monkeypox Virus Proteins – Accelerate Monkeypox Research.
WHO Director-General declares mpox outbreak a public health emergency of international concern